Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

作者：Zinan Zhao, Naixin Zheng, Tianqi Zhang, Chi Zhang, Yuwei Li, Ming Lan, Ni Zhang, Hui Li, Hu Ai, Deping Liu · 发表于：Cardiovascular Diabetology · 年份：2025 · DOI：10.1186/s12933-025-02678-9 · 被引用次数：5 · 研究领域：Diabetes Treatment and Management、Hyperglycemia and glycemic control in critically ill and hospitalized patients、Chronic Kidney Disease and Diabetes

IMPORTANCE: Although sodium‒glucose cotransporter-2 (SGLT2) inhibitors have cardiorenal benefits, their efficacy in patients with type 2 diabetes mellitus (T2DM) and chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) remains underexplored. OBJECTIVE: To evaluate the cardiorenal protective effects of the SGLT2 inhibitor dapagliflozin in patients with T2DM and CCS receiving PCI. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional analysis of 1,430 patients from a tertiary hospital database who underwent PCI (January 1, 2018, to March 31, 2022). MAIN OUTCOMES AND MEASURES: Cardiac outcomes (PMI/4aMI) and renal outcomes (eGFR and CI-AKI). RESULTS: ) were not significantly different before or after PSM or after adjustment (all p > 0.05). CONCLUSIONS AND RELEVANCE: Dapagliflozin exerted robust cardioprotective effects against PMI/4aMI in patients with T2DM and CCS undergoing PCI, particularly among patients in high-risk subgroups, but it did not significantly reduce the risk of CI-AKI. These findings support the peri-PCI use of dapagliflozin to mitigate cardiac risk while highlighting the need for further research to elucidate its renal effects in this population.